Loading patent…
AssigneeInstituto di Richerche di Biologia Molecolare P. Angeletti SpA
InventorsLuigi Aurisicchio, Daniela Peruzzi, Nicola La Monica, Gennaro Ciliberto, Domenico Lazzaro, Federica Mori
Estimating the term…
Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
An isolated nucleic acid comprising a nucleotide sequence encoding a human matrix metalloproteinase 11 (MMP-11) protein, said protein comprising the sequence of amino acids as set forth in SEQ ID NO:5, wherein one or more of the nucleotide codons have been optimized for enhanced expression of the nucleic acid in cells of human origin.
An isolated nucleic acid encoding a fusion polypeptide having a matrix metalloproteinase 11 (MMP-11) linked to a subunit B of heat labile toxin (LTB) of E. coli wherein the LTB does not include a signal peptide and wherein the LTB is encoded by the nucleotide sequence as set forth in SEQ ID NO:8.
Dependencies are inferred from the claim text.